

factors of group B are similar to group A; more ER negativity and more chemotherapy but their prognosis is better than group A.

Conclusions: Although this study is retrospective, the age of 35 is important prognostic factor in stage I breast cancer.

150

Poster

Prognostic importance of metastasis to level III lymph node with less than 10 metastasized lymph nodes in the N3 breast cancer

S.H. Kang¹, Y.S. Jeon¹, Y.S. Cho¹, C.H. Kim¹, S.J. Lee¹, Y.K. Bae².

¹Yeungnam University College of Medicine, Department of Surgery, Daegu, Korea; ²Yeungnam University College of Medicine, Department of Pathology, Daegu, Korea

Background: The American Joint Committee on Cancer (AJCC) TNM System is the most common system used to describe the stages of breast cancer. According to this system, metastasis to level III (infraclavicular or subclavicular) axillary lymph nodes belongs to N3. However, its prognostic value still remains controversial. The aim of current study is to investigate the clinicopathologic features and prognosis of level III lymph node metastasis with less than 10 metastasized nodes.

Materials and Methods: Four hundred and fifty five breast cancer patients (N2 or N3 stages on final histology) underwent operations from January 1990 to December 2007 at our institution were included in this study. The patients were categorized into 3 groups by the number of metastatic lymph nodes and level of invasion: *N2 group* (level I or II patients with 4–9 metastatic nodes), *level III group* (metastasis to level III with less than 10 metastatic nodes) and *N3 group* (10 or more metastatic nodes). Clinicopathologic features of level III group were analyzed and survival rate of the level III group was compared with those of N2 and N3 groups.

Results: The mean age of patients at diagnosis was 46.0 years (ranging from 20 to 78) and the mean follow-up was 63.1 months. Five-year disease free survival (5-yr DFS) rates for level III metastatic patients and non-level III metastatic patients were 51.2% and 70.2%, respectively ($p < 0.001$). Five-year overall survival rates (5-yr OS) for the same patient groups were 70.2% and 83.2%, respectively ($p < 0.001$). Level III invasion was significantly related to larger tumor size ($p = 0.018$), 10 or more metastasized lymph nodes ($p < 0.001$ and relative risk=10.06) and positive Her-2 status ($p = 0.005$). Nevertheless, the only independent risk factor involved in level III invasion was 10 or more metastatic lymph nodes ($p < 0.001$ and relative risk=10.06). 5-yr DFS for N2, level III and N3 groups were 73.9%, 60.2% and 48.1%, respectively ($p < 0.001$) and 5-yr OS for the same groups were 86.2%, 76.0% and 60.7%, respectively ($p < 0.001$). There was significant difference between level III and N3 group for OS ($p = 0.023$). However, there was no survival difference between N2 and level III group.

Conclusion: The prognosis of breast cancer patients with level III lymph node metastasis having less than 10 metastatic nodes is similar to the prognosis of N2 group, and is better than the prognosis of N3 patients with 10 or more metastasized nodes. In conclusion, the number of metastatic axillary lymph nodes is a more important predictor of mortality than the level of invasion in N3 breast cancer.

151

Poster

Is 70-gene prognostic signature in breast cancer for Korean different from European?

K.Y. Na¹, K.S. Kim¹, J.M. Park¹, J.Y. Kim¹, M.S. Kim¹, J.E. Lee², H.J. Kim³, B.I. Moon⁴, K. Kwak⁵, K. Park⁶. ¹Ajou university medical center, surgery, Suwon, Korea; ²University School of Medicine, surgery, Seoul, Korea; ³University of Ulsan College of Medicine and Asan Medical Center, Surgery, Seoul, Korea; ⁴Ewha Womans' University Mokdong Hospital School of Medicine, Surgery, Seoul, Korea; ⁵Inje University Sanggye Paik Hospital, Surgery, Seoul, Korea; ⁶Inje University Sanggye Paik Hospital, Pathology, Seoul, Korea

Background: A 70-gene prognosis signature was previously shown to have prognostic value in patients with node-negative breast cancer in Europe. But there is no study about a 70-gene prognosis signature in Asian. We therefore investigated whether the 70-gene prognosis-signature can identify patients with node negative who have an excellent disease outcome or not.

Material and Methods: Between March, 2008 and September, 2009, 47 patients with breast cancer (clinical T1–2N0M0) were selected from four hospitals in Korea. Fresh tumor samples were analyzed with customized microarray for the 70-gene tumor expression signature.

Concordance between risk predicted by the 70-gene prognosis signature and risk predicted by commonly used clinicopathologic guidelines (St. Gallen guidelines, NIH guideline, Adjuvant! Online) was evaluated. Also we analyzed clinicopathologic features of patients compared with previous validation study.

Results: Of 47 eligible patients, 12 patients were excluded because of sampling failure ($n = 10$) and lymph node metastasis on permanent pathologic finding ($n = 2$). Prognosis signatures were assessed in 35 patients. There were no significant differences in clinicopathologic features of patients compared with previous studies. The 70-gene prognosis signature identified 5 (14.3%) patients with good prognosis and 30 (85.7%) patients with poor prognosis. Tumors with a poor prognosis-signature were more often classified as HER-2 positive tumor, high histologic grade and large tumor size.

The St. Gallen guidelines identified patients 29 (82.9%) with poor prognosis, which was concordant with those findings obtained with the prognosis signature in 28 (80%) patients. NIH guidelines identified 30 (85.7%) patients with poor prognosis with the signature and concordance in 29 (82.9%) patients. Adjuvant! Online guidelines identified 14 (40%) patients with good prognosis than did the signature alone and concordance with the signature occurred in 22 (62.9%) patients. Concordance rate between risks predicted by the prognosis signature and commonly used clinicopathologic guidelines was about 60–80%.

Conclusions: Our results are different from previous validation studies in Europe with about 40% good prognosis and about 60% poor prognosis. This difference should be studied whether the disparity of gene between Asian and European has influence to that or not.

Our results were the first data of gene prognosis signature in Asian breast cancer patients, but the small number of the cases, no data of follow-up and no assessment of predictive value of the prognosis signature are the limitations of the current study. Further investigation is required to overcome these limitations and to assess whether use of the 70-gene prognosis signature can predict prognosis of patients in Asian as well as European.

152

Poster

Predictive value of bone marrow micrometastasis detected by nested RT-PCR for cytokeratin 19 in breast cancer patients

J.M. Park¹, K.S. Kim¹, L.N. Hur², K.Y. Na¹, J.Y. Kim¹, K.K. Oh³, H.E. Yim⁴, S.Y. Kang⁵, M. Jun⁶, Y.S. Jung¹. ¹Ajou University Hospital, Surgery, Suwon, South Korea; ²Seoul Adventist Hospital, Surgery, Seoul, South Korea; ³Ajou University Hospital, Radiology, Suwon, South Korea; ⁴Ajou University Hospital, Pathology, Suwon, South Korea; ⁵Ajou University Hospital, Haematology and Oncology, Suwon, South Korea; ⁶Ajou University Hospital, Radiation Oncology, Suwon, South Korea

Background: In breast cancer patients, systemic relapse may occur during the early phase. Some studies have shown a correlation between the presence of micrometastasis in bone marrow and the clinical outcome of patients. We previously reported prognostic value of cytokeratin 19 in early recurrence. The purpose of this study was to reestablish the meaning of cytokeratin 19 mRNA in bone marrow aspirates and their possible correlation with distant disease free survival in long term follow up.

Materials and Methods: Between June 2001 and December 2003, bone marrow samples were obtained from 248 breast cancer patients at the time of surgery. These patients had undergone breast operation and bone marrow aspiration from the iliac spine and were treated and subjected to follow-up studies similarly to other breast cancer patients, regardless of the results of the bone marrow reverse transcriptase polymerase reaction (RT-PCR) study. We separated the mononuclear fraction from the samples and carried out nested RT-PCR for the detection of cytokeratin 19 mRNA using two different pairs of primers. The clinical and pathological data and the results of the bone marrow cytokeratin 19 nested RT-PCR was reviewed and analyzed together with clinical results on distant metastasis free survival and overall survival.

Results: The median follow up time was 66 months. The median age of patients was 46 years old. Sixty-six (26.6%) of the 248 samples were cytokeratin-19 positive. According to staging, twenty cases (25.6%) were positive among 78 patients with stage I, 33 cases (28.4%) in 116 patients with stage II and 13 cases (28.9%) in 45 patients with stage III. However, no statistical significance was found between bone marrow micrometastasis and tumor size, lymph node metastasis and stage. Sixteen patients (24.3%) in the 66 cytokeratin 19 positive group showed systemic relapse. Twenty three patients (12.5%) in the 182 cytokeratin 19 negative group showed systemic relapse. Cytokeratin 19 positive group have shorter distant disease free survival rate than cytokeratin 19 negative group ($p = 0.015$). However, there was no statistically significant difference in overall survival ($p = 0.079$).

Conclusions: The nested RT-PCR of keratin 19 for micrometastasis of breast cancer showed high sensitivity for micrometastasis of bone marrow. Detection of occult micrometastasis in bone marrow using nested RT-PCR assay for cytokeratin 19 could be useful predictive factor for the systemic breast cancer relapse.